Prothena (STU:0PT) Tariff Resilience Score: 6/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0PT Prothena Corp PLC STU:0PT
74 GF Score
Price €7.57
GF Value €12.74
! 3 Warning Signs
View Full Analysis

What is Prothena Tariff Resilience Score?

Prothena STU:0PT +2.49% 74 Tariff Resilience Score is 6 as of Jul. 18, 2026. GuruFocus rates STU:0PT with a GF Score™ of 74/100 and a GF Value™ of €12.74. The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, Prothena ranks better than 75.99% on this metric.

Prothena has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Prothena has Biotech firm with some global supply chain dependencies. While R&D is primarily domestic, potential international partnerships and material imports could be affected by tariffs. Mitigation through alternative suppliers is possible.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Prothena might have Average Resilient.

Prothena  (STU:0PT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Prothena Tariff Resilience Score Related Terms

STU:0PT vs CTNM, ASMB, ARVN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Prothena's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prothena Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Prothena's Tariff Resilience Score falls into.


STU:0PT
74GF Score
Prothena Corp PLC STU:0PT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Prothena (STU:0PT) has a Tariff Resilience Score of 6 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Prothena ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Prothena's Tariff Resilience Score too high?
Prothena's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Prothena's value of 6 is 50% above this industry median. Based on the distribution chart, Prothena ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Prothena has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Tariff Resilience Score compare to CTNM and ASMB?
According to the Biotechnology industry distribution chart, Prothena ranks #329 out of 1370 companies for Tariff Resilience Score. This places Prothena in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Prothena's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prothena's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prothena's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (STU:0PT) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €12.74, compared to a current price of €7.57 — trading 40.6% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Prothena's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Prothena (STU:0PT), the current Tariff Resilience Score is 6 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €7.57 is trading 40.6% below its estimated GF Value™ of €12.74.

Key valuation signals for STU:0PT:

  • Tariff Resilience Score: 6
  • GF Value™: €12.74 vs. price of €7.57 (40.6% below fair value)
  • GF Score™: 74/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for STU:0PT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.57
Price
€12.74
GF Value